Want to see JP:4591 full AI Analyst Report?
4591 Stock Chart & Stats
¥75.00
¥23.00(27.71%)
At close: 4:00 PM EST
¥75.00
¥23.00(27.71%)
Day’s Range― - ―
52-Week Range¥57.00 - ¥120.00
Previous CloseN/A
Volume38.87M
Average Volume (3M)407.30K
Market Cap
¥3.75B
Enterprise Value¥610.54M
Total Cash (Recent Filing)¥2.78B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.85
Shares Outstanding56,832,640
10 Day Avg. Volume428,780
30 Day Avg. Volume407,296
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)1.54
Price to Sales (P/S)1456.29
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Net-cash Balance SheetA net-cash position and zero debt reduce financial risk compared with leveraged peers, preserving flexibility to fund research and operations without immediate refinancing pressure. This provides a durable financial cushion even though ongoing losses are consuming part of the equity base.
Revenue ReboundThe latest annual revenue rebound indicates that the company has demonstrated some ability to expand sales from its earlier low base. If sustained, stronger revenue could improve operating leverage and help convert the early-stage business model into a more viable commercial platform.
Periods Of Improved Cash BurnIntermittent improvement in cash-burn intensity suggests operating discipline or changing funding needs can reduce the pace of cash consumption. That is a useful positive for runway management, although it remains supportive rather than decisive while operating and free cash flow stay negative.
Bears Say
Persistent UnprofitabilityPersistent operating and net losses show that the current revenue base is not yet sufficient to support the expense structure. Without clear evidence of approaching break-even, the company may continue consuming capital and remain financially dependent on its existing resources or future equity funding.
Structural Cash BurnConsistently negative operating and free cash flow means the business is not currently self-funding its operations. Because cash flow broadly follows net losses, there is limited non-cash cushioning, increasing the importance of available cash and future financing capacity for ongoing development.
Eroding Equity BaseA declining equity base indicates that accumulated losses are steadily reducing the company’s financial capital despite its debt-free position. Continued erosion can narrow the buffer available for research and operations, while increasing the potential need for external capital to sustain the business.
Ribomic, Inc. News
4591 FAQ
What was Ribomic, Inc.’s price range in the past 12 months?
Ribomic, Inc. lowest stock price was ¥57.00 and its highest was ¥120.00 in the past 12 months.
What is Ribomic, Inc.’s market cap?
Ribomic, Inc.’s market cap is ¥3.75B.
When is Ribomic, Inc.’s upcoming earnings report date?
Ribomic, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 18 days.
How were Ribomic, Inc.’s earnings last quarter?
Ribomic, Inc. released its earnings results on Aug 13, 2026. The company reported -¥4.87 earnings per share for the quarter.
Is Ribomic, Inc. overvalued?
According to Wall Street analysts Ribomic, Inc.’s price is currently Overvalued.
Does Ribomic, Inc. pay dividends?
Ribomic, Inc. does not currently pay dividends.
What is Ribomic, Inc.’s EPS estimate?
Ribomic, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ribomic, Inc. have?
Ribomic, Inc. has 56,832,640 shares outstanding.
What happened to Ribomic, Inc.’s price movement after its last earnings report?
Ribomic, Inc. reported an EPS of -¥4.87 in its last earnings report. Following the earnings report the stock price went down -1.299%.
Which hedge fund is a major shareholder of Ribomic, Inc.?
Currently, no hedge funds are holding shares in JP:4591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ribomic, Inc.
Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma. Furthermore, Ribomic manufactures specialized separating agents used for the affinity purification of human IgG and Fc-fusion proteins. Established in 2003, the company's main operations are based in Tokyo, Japan.